SCHEDULE: ING Entities Report 7.05% Stake in Tenax Therapeutics

ING Groep N.V. and its subsidiary ING Capital Markets LLC have reported beneficial ownership of 7.05% of Tenax Therapeutics, Inc. common stock.

Summary

• ING Groep N.V. and its wholly-owned subsidiary, ING Capital Markets LLC, have jointly filed a Schedule 13G.
• This filing indicates that ING Capital Markets LLC beneficially owns 2,639,666 shares of Tenax Therapeutics, Inc. common stock.
• This ownership represents approximately 7.05% of the total outstanding common stock.
• The filing is based on the issuer's reported share count as of July 28, 2026, from its Form 10-Q filed on July 31, 2026.
• Neither ING Groep N.V. nor ING Capital Markets LLC holds sole voting or sole dispositive power over these shares; all are held under shared voting and shared dispositive power.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership percentage without providing new operational or financial performance data.

Positives

• Significant institutional ownership by ING entities can sometimes signal confidence or a strategic interest in the company's future.

Negatives

• The filing does not provide any new financial performance data or operational updates for Tenax Therapeutics, Inc.

Risks

• The primary risk is that the ownership stake could be part of a larger strategy that may or may not align with all shareholder interests.
• Changes in beneficial ownership, even if not for control, can sometimes precede other strategic moves that may impact the stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Tenax Therapeutics, Inc. It solely reports on the beneficial ownership of ING entities.

Management Comments

• ING Groep N.V. may be deemed to be the beneficial owner of 2,639,666 Common Stock, held by ING Capital Markets LLC, a wholly owned subsidiary of ING Groep N.V.
• ING Capital Markets LLC may be deemed to be the beneficial owner of 2,639,666 Common Stock.
• Each of ING Groep N.V. and ING Capital Markets LLC may be deemed to be the beneficial owner of approximately 7.05% of Common Stock issued and outstanding as of July 28, 2026.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake acquisitions or changes in beneficial ownership by large financial institutions like ING can be a signal in the biotechnology sector, which is often characterized by substantial capital requirements and strategic partnerships. However, without further context on ING's investment strategy for Tenax Therapeutics, the impact remains speculative.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, potentially leading to increased liquidity or strategic focus, but the lack of operational details leaves room for uncertainty.
• Creditors: Unlikely to be directly impacted by this filing as it pertains to equity ownership and not debt.
• Employees: No direct impact indicated by this filing.
• Customers/Suppliers: No direct impact indicated by this filing.

Next Steps

• Monitor future filings from ING Groep N.V. and ING Capital Markets LLC for any changes in their stake.
• Observe Tenax Therapeutics, Inc.'s subsequent disclosures for any strategic implications arising from this ownership.

Key Dates

Keywords

Tenax Therapeutics, ING Groep N.V., ING Capital Markets LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock